Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 C/EBPα deregulation as a paradigm for leukemogenesis.

Literature DB >> 28720765

C/EBPα deregulation as a paradigm for leukemogenesis.

Abstract

Myeloid master regulator CCAAT enhancer-binding protein alpha (C/EBPα) is deregulated by multiple mechanisms in leukemia. Inhibition of C/EBPα function plays pivotal roles in leukemogenesis. While much is known about how C/EBPα orchestrates granulopoiesis, our understanding of molecular transformation events, the role(s) of cooperating mutations and clonal evolution during C/EBPα deregulation in leukemia remains elusive. In this review, we will summarize the latest research addressing these topics with special emphasis on CEBPA mutations. We conclude by describing emerging therapeutic strategies to restore C/EBPα function.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28720765 PMCID： PMC8197657 DOI： 10.1038/leu.2017.229

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

81 in total

1. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.

Authors: Steffen Koschmieder; Francesco D'Alò; Hanna Radomska; Christine Schöneich; Ji Suk Chang; Marina Konopleva; Susumu Kobayashi; Elena Levantini; Nanjoo Suh; Annalisa Di Ruscio; Maria Teresa Voso; Julie C Watt; Ramasamy Santhanam; Bülent Sargin; Hagop Kantarjian; Michael Andreeff; Michael B Sporn; Danilo Perrotti; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve; Daniel G Tenen
Journal: Blood Date: 2007-08-01 Impact factor: 22.113

2. Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model.

Authors: K Reckzeh; O Bereshchenko; A Mead; M Rehn; S Kharazi; S-E Jacobsen; C Nerlov; J Cammenga
Journal: Leukemia Date: 2012-02-09 Impact factor: 11.528

3. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.

Authors: T Pabst; B U Mueller; P Zhang; H S Radomska; S Narravula; S Schnittger; G Behre; W Hiddemann; D G Tenen
Journal: Nat Genet Date: 2001-03 Impact factor: 38.330

4. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1.

Authors: Oren Ben-Ami; Dan Friedman; Dena Leshkowitz; Dalia Goldenberg; Kira Orlovsky; Niv Pencovich; Joseph Lotem; Amos Tanay; Yoram Groner
Journal: Cell Rep Date: 2013-09-19 Impact factor: 9.423

5. Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors: Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal: N Engl J Med Date: 2004-04-15 Impact factor: 91.245

6. Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment.

Authors: Janki Rangatia; Rajani Kanth Vangala; Nicolai Treiber; Pu Zhang; Hanna Radomska; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Journal: Mol Cell Biol Date: 2002-12 Impact factor: 4.272

7. RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.

Authors: Nathalie Girard; Mathieu Tremblay; Magali Humbert; Benoît Grondin; André Haman; Jean Labrecque; Bing Chen; Zhu Chen; Sai-Juan Chen; Trang Hoang
Journal: Proc Natl Acad Sci U S A Date: 2013-07-29 Impact factor: 11.205

8. Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.

Authors: Jens Tiesmeier; Andreas Czwalinna; Carsten Müller-Tidow; Jürgen Krauter; Hubert Serve; Gerhard Heil; Arnold Ganser; Walter Verbeek
Journal: Br J Haematol Date: 2003-11 Impact factor: 6.998

9. Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Authors: Kiran Tawana; Jun Wang; Aline Renneville; Csaba Bödör; Robert Hills; Chey Loveday; Aleksandar Savic; Frederik W Van Delft; Jennifer Treleaven; Panayiotis Georgiades; Elizabeth Uglow; Norio Asou; Naokuni Uike; Maruša Debeljak; Janez Jazbec; Philip Ancliff; Rosemary Gale; Xavier Thomas; Valerie Mialou; Konstanze Döhner; Lars Bullinger; Beatrice Mueller; Thomas Pabst; Matthias Stelljes; Brigitte Schlegelberger; Eva Wozniak; Sameena Iqbal; Jessica Okosun; Shamzah Araf; Anne-Katrine Frank; Felicia B Lauridsen; Bo Porse; Claus Nerlov; Carolyn Owen; Inderjeet Dokal; John Gribben; Matthew Smith; Claude Preudhomme; Claude Chelala; Jamie Cavenagh; Jude Fitzgibbon
Journal: Blood Date: 2015-07-10 Impact factor: 22.113

10. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.

Authors: Hanna S Radomska; Daniela S Bassères; Rui Zheng; Pu Zhang; Tajhal Dayaram; Yukiya Yamamoto; David W Sternberg; Nathalie Lokker; Neill A Giese; Stefan K Bohlander; Susanne Schnittger; Marie-Hélène Delmotte; Roger J Davis; Donald Small; Wolfgang Hiddemann; D Gary Gilliland; Daniel G Tenen
Journal: J Exp Med Date: 2006-01-30 Impact factor: 14.307

18 in total

Review 1. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

Authors: Anuradha Kirtonia; Gouri Pandya; Gautam Sethi; Amit Kumar Pandey; Bhudev C Das; Manoj Garg
Journal: J Mol Med (Berl) Date: 2020-07-03 Impact factor: 4.599

Review 2. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors: Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal: Blood Date: 2020-07-02 Impact factor: 22.113

Review 3. Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors: Jane E Churpek; Emery H Bresnick
Journal: J Clin Invest Date: 2019-02-01 Impact factor: 14.808

Review 4. Emerging therapies for inv(16) AML.

Authors: Sridevi Surapally; Daniel G Tenen; John A Pulikkan
Journal: Blood Date: 2021-05-13 Impact factor: 22.113

5. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.

Authors: Katherine Tarlock; Adam J Lamble; Yi-Cheng Wang; Robert B Gerbing; Rhonda E Ries; Michael R Loken; Lisa Eidenschink Brodersen; Laura Pardo; Amanda Leonti; Jenny L Smith; Tiffany A Hylkema; William G Woods; Todd M Cooper; E Anders Kolb; Alan S Gamis; Richard Aplenc; Todd A Alonzo; Soheil Meshinchi
Journal: Blood Date: 2021-09-30 Impact factor: 25.476

Review 10. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.

Authors: Anna S Wilhelmson; Bo T Porse
Journal: Br J Haematol Date: 2020-02-21 Impact factor: 6.998